Ahmed Elkoulily, MD
Internal Medicine · Lynbrook, NYNPI 1346225927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amarin Pharma, Inc. accounts for 63.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $325 and has fallen 92.3% since, to $25 in 2025.
Across 15 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$313
- Indivior Inc.$69
- AstraZeneca$30
- Lundbeck LLC$25
- Lilly USA, LLC$19
- Amgen$19
- plus $18 from 1 others
What the payments were for
- Food & beverage$493100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 6 | $313 |
| Indivior Inc. | 3 | $69 |
| AstraZeneca | 2 | $30 |
| Lundbeck LLC | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
| Amgen | 1 | $19 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$241
How this compares
$493 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 17 | $24,342 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $2,177 |
| Atorvastatin Calcium | 159 | $1,330 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,271 |
| Metoprolol Succinate | 62 | $791 |
| Levothyroxine Sodium | 64 | $725 |
| Omeprazole | 58 | $675 |
| Amlodipine Besylate | 118 | $590 |
| FenofibrateFenofibrate,micronized | 13 | $533 |
| Metformin Hcl | 121 | $465 |
| Losartan Potassium | 58 | $446 |
| Fluticasone Propionate | 48 | $427 |
| Gabapentin | 16 | $381 |
| Lisinopril | 80 | $351 |
| Simvastatin | 46 | $296 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Lynbrook
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.